Li Yunchun, chairman of the board of directors, said: “we will have the most varieties of 3002 vaccines in China in the 10th and 21st year. By 2021, we will have the most varieties of 3002 vaccines.”
At present, Walvax Biotechnology Co.Ltd(300142) has achieved remarkable results in the comprehensive layout of mRNA, recombinant protein, new adjuvant, recombinant adenovirus vector and other technical platforms: the annual sales of self-developed vaccine products have increased significantly, and the “small targets” in the process of developing heavy vaccine products have been implemented one by one.
product strength: meet three vaccine R & D “milestones”
Why take off? Those who are strong in arms and horses do it. And Walvax Biotechnology Co.Ltd(300142) is stronger in product strength.
At the beginning of the Spring Festival, Walvax Biotechnology Co.Ltd(300142) announced a number of vaccine product research and development progress: the sales revenue of 13 valent pneumonia conjugate vaccine (hereinafter referred to as “pcv13”) increased by about 66% year-on-year, opening the overseas market journey from Morocco; The CDE review of HPV-2 vaccine has been completed, or it may become the second domestic HPV vaccine in China; The domestic mRNA vaccine of covid-19 mutant will be developed jointly with blue magpie biology.
The announcement shows that the sales revenue of pcv13 independently developed by Walvax Biotechnology Co.Ltd(300142) in 2020 will be 1.658 billion yuan; According to the performance forecast data of 2021, the sales revenue of pcv13 increased by 66% year-on-year, and the sales revenue of the vaccine product may increase to 2.752 billion yuan; In 2020, Walvax Biotechnology Co.Ltd(300142) and Pfizer’s pcv13 were issued in batches of 4.4651 million and 6.4235 million in China respectively; With the growth of Walvax Biotechnology Co.Ltd(300142) pcv13 sales, it is expected to surpass the market share occupied by Pfizer’s similar products in 2021.
In 2022, pcv13 produced by Walvax Biotechnology Co.Ltd(300142) can be officially exported to Morocco, becoming a new increment of the company’s vaccine sales and an important step for the vaccine product to enter the international market. Walvax Biotechnology Co.Ltd(300142) also said that the sales of pcv13 in Morocco will have a positive impact on the company’s current and future operating performance.
On the other hand, Li Yunchun also said: ” Walvax Biotechnology Co.Ltd(300142) the last light of the drug (CDE) review of the HPV-2 vaccine independently developed by the State Drug Administration has been extinguished.” If Walvax Biotechnology Co.Ltd(300142) HPV-2 vaccine passes the CDE review, the company will add another heavy vaccine product to become the second HPV vaccine independently developed in China.
national attention: covid-19 mRNA vaccine partner “circle of friends” refresh
The research and development progress of covid-19 mRNA vaccine is closely related to “universal immunization”, which is also the most concerned aspect of Walvax Biotechnology Co.Ltd(300142) investors.
Walvax Biotechnology Co.Ltd(300142) said that the phase III clinical trial of China’s first mRNA covid-19 vaccine jointly developed by the company and its partners was conducted simultaneously in China International, and the sequential penetration groups in Yunnan and Guangxi have been completed.
At the same time, Walvax Biotechnology Co.Ltd(300142) also disclosed cooperation with blue magpie organisms to jointly develop New Coronavirus mutant mRNA vaccine product development and commercial cooperation.
Walvax Biotechnology Co.Ltd(300142) taking the layout of mRNA technology as the company’s strategic choice, the company has expanded the vaccine cooperation varieties of mRNA technology platform on the basis of cooperating with Aibo biology to develop the prototype covid-19 mRNA vaccine, cooperating with Cheng Du Sheng Nuo Biotec Co.Ltd(688117) to develop siRNA drugs, and cooperating with blue magpie biology to develop RSV and influenza mRNA vaccine.
Li Yunchun also said: “the global outbreak of Omicron mutant has a strong escape ability to the existing vaccine, and higher protective efficacy vaccines and better immunization strategies are needed to meet the challenge of Omicron outbreak in China and even the world.” Covid-19 mRNA vaccine has the advantages of high efficiency and rapid iteration. It is the most potential vaccine technical route to deal with Omicron and possible new variants in the future.
The “foundation” of the multi-level layout of Walvax Biotechnology Co.Ltd(300142) R & D pipeline stems from the company’s R & D and innovation strength. In 2021, Walvax Biotechnology Co.Ltd(300142) R & D investment in new products and new projects increased. China and foreign clinical trials of key R & D projects are being promoted, and the R & D expenses increased by about 256% compared with the same period of last year. Although it diluted the profit space of the company, it also maintained the competitive advantage of independent R & D.
